[Pulmonary hypertension in connective tissue disease]

Area of Science:

• Rheumatology
• Cardiology
• Pulmonology

Background:

• Pulmonary arterial hypertension (PAH) is a significant complication of systemic sclerosis (SSc).
• Early detection and treatment of SSc-PAH are vital for improving patient prognosis.
• PAH can manifest across all stages and subsets of SSc.

Purpose of the Study:

• To emphasize the importance of screening for pulmonary arterial hypertension in patients with systemic sclerosis.
• To highlight the benefits of early diagnosis and targeted therapy for SSc-PAH.
• To outline the recommended diagnostic and management strategies for SSc-PAH.

Main Methods:

• Recommended screening tests include echocardiography, diffusion capacity, brain natriuretic protein (BNP), and a 6-minute walking test.
• Right heart catheterization is essential for confirming suspected PAH diagnosis.
• A multidisciplinary approach involving rheumatologists, respiratory physicians, and specialized cardiologists is mandatory.

Main Results:

• Clinical symptoms of PAH are often nonspecific and appear late.
• Early detection through screening enhances the suspicion of PAH.
• Prompt initiation of disease-targeted drug therapy can modify disease progression.

Conclusions:

• Regular screening for PAH in SSc patients is recommended.
• Early diagnosis and treatment lead to a better prognosis for SSc-PAH.
• Expert multidisciplinary care is essential for managing SSc patients at risk for or with PAH.